Pirtobrutinib(Jaypirca)

Pirtobrutinib received accelerated approval from the U.S. FDA on January 27, 2023. As a prescription drug targeting Bruton's tyrosine kinase (BTK), it must be used strictly under medical supervision.

Target of Action

Bruton's tyrosine kinase (BTK)

Dosage and Administration

Route and frequency of administration for Pirtobrutinib: oral, once daily.

The dose of Pirtobrutinib should be adjusted based on the patient's actual condition; specific adjustments require consultation with a physician and adherence to medical advice.

Recommended reading: Dosage and Administration of Pirtobrutinib

Side Effects

Common side effects: decreased white blood cell count, decreased red blood cell count, fatigue, etc.

Serious side effects: infections, bleeding, decreased blood cell counts, etc.

Reference article: Side Effects of Pirtobrutinib

Use in Special Populations

Pregnancy: Women of childbearing potential should use effective contraception during treatment with Pirtobrutinib and for at least 1 week after the last dose. If you become pregnant or suspect you are pregnant during treatment, inform your doctor immediately.

Breastfeeding: It is not known whether Pirtobrutinib passes into breast milk. Do not breastfeed during treatment and for at least 1 week after the last dose.

Daily Precautions

1. Instruct patients to take Pirtobrutinib once daily at approximately the same time each day, with or without food. If a dose is missed, it should be taken as soon as possible on the same day. If more than 12 hours have passed, skip the missed dose and take the next dose at the regularly scheduled time the following day. Advise patients to swallow the tablet whole with water, and not to break, crush, or chew the tablet.

2. Inform the clinician if any signs or symptoms of bleeding occur. If any surgery is planned, notify the physician in advance; Pirtobrutinib may need to be withheld before major surgery.

3. Inform the clinician promptly if signs or symptoms suggestive of infection (e.g., fever, chills, fatigue, etc.) appear.

from FDA，2024.06